Share this article
Share this article
TOKYO and CAMBRIDGE, England, Feb. 1, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ; TSE: 4565) announces it will apply its world-leading structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new strategic collaboration with Metrion Biosciences Limited ( Metrion ), the specialist ion channel CRO and drug discovery company.
Ion channels are a class of integral membrane proteins that regulate the flow of ions across the cell membrane as a means of conducting signals between cells and their environment. They are well established drug targets, particularly in neurological and cardiovascular diseases, but many remain undrugged or poorly drugged, and may be tractable to structure-based approaches.
Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
- Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders
- Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe
News provided by
Share this article
Share this article
TOKYO and CAMBRIDGE, England, Dec. 22, 2020 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor Therapeutics SA ( Captor ; Wroclaw, Poland and Allschwil, Switzerland), a European leader in targeted protein degradation, have entered a strategic technology collaboration focused on the discovery and development of novel small molecules that target the degradation of disease-associated G protein-coupled re